Ligand To Host Analyst Day On December 4th In New York City

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day in New York City on Tuesday, December 4, 2012 from 10:30 a.m. to 12:00 p.m. Eastern Time (7:30 a.m. to 9:00 a.m. Pacific Time). The event will feature presentations pertaining to the Company’s business and pipeline programs. The event will take place at the Concierge Conference Center, located at 780 Third Avenue.

The presentations will be webcast live and can be accessed at www.ligand.com. A replay of this webcast will be available for 30 days following the event.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company that develops and acquires assets it believes will generate royalty revenues and, under its lean corporate cost structure, produce sustainable profitability. Ligand has a diverse asset portfolio addressing the unmet medical needs of patients for a broad spectrum of diseases including thrombocytopenia, multiple myeloma, diabetes, hepatitis, muscle wasting, dyslipidemia, anemia, and osteoporosis. Ligand’s Captisol ® platform technology is a patent protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world’s leading pharmaceutical companies including GlaxoSmithKline, Merck, Pfizer, Eli Lilly & Company, Baxter International, Bristol-Myers Squibb, Celgene, Onyx Pharmaceuticals, Lundbeck Inc., The Medicines Company, Curis, Inc. and Rib-X Pharmaceuticals. Please visit www.captisol.com for more information on Captisol. For more information on Ligand, please visit www.ligand.com.

Follow Ligand on Twitter @Ligand_LGND.

Copyright Business Wire 2010

If you liked this article you might like

6 Stocks with Unusual Volume Activity

6 Stocks with Unusual Volume Activity

6 Stocks on the Move With Unusual Volume

6 Stocks on the Move With Unusual Volume

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease

Analysts' Actions -- ConocoPhillips, Discover, DineEquity, Maxim and More

Analysts' Actions -- ConocoPhillips, Discover, DineEquity, Maxim and More